BioCryst Pharmaceuticals Current Valuation vs. Cash And Equivalents
| BCRX Stock | USD 7.46 0.07 0.93% |
For BioCryst Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioCryst Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioCryst Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioCryst Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioCryst Pharmaceuticals over time as well as its relative position and ranking within its peers.
BioCryst |
BioCryst Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Revenue Per Share 2.01 | Quarterly Revenue Growth 0.35 | Return On Assets (0.04) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioCryst Pharmaceuticals Cash And Equivalents vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioCryst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare BioCryst Pharmaceuticals value to that of its competitors to determine the firm's financial worth. BioCryst Pharmaceuticals is rated below average in current valuation category among its peers. It is rated fourth in cash and equivalents category among its peers creating about 0.20 of Cash And Equivalents per Current Valuation. The ratio of Current Valuation to Cash And Equivalents for BioCryst Pharmaceuticals is roughly 4.88 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioCryst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.BioCryst Current Valuation vs. Competition
BioCryst Pharmaceuticals is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 48.04 Billion. BioCryst Pharmaceuticals holds roughly 2.04 Billion in current valuation claiming about 4% of equities under Health Care industry.
BioCryst Cash And Equivalents vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
BioCryst Pharmaceuticals |
| = | 2.04 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
BioCryst Pharmaceuticals |
| = | 417.48 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
BioCryst Cash And Equivalents Comparison
BioCryst Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
BioCryst Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioCryst Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioCryst Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of BioCryst Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of BioCryst Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.3 M | 1.4 M | |
| Operating Income | -103.7 M | -98.5 M | |
| Net Loss | -226.5 M | -215.2 M | |
| Income Tax Expense | 310 K | 325.5 K | |
| Total Other Income Expense Net | -122.5 M | -128.6 M | |
| Income Before Tax | -226.2 M | -237.5 M | |
| Net Loss | -236.3 M | -224.5 M | |
| Non Operating Income Net Other | 63.4 M | 66.6 M | |
| Net Loss | -222.4 M | -211.3 M | |
| Interest Income | 14 M | 14.7 M | |
| Net Interest Income | -96.1 M | -91.3 M | |
| Change To Netincome | 163.1 M | 171.3 M | |
| Net Loss | (1.18) | (1.24) | |
| Income Quality | 0.42 | 0.40 | |
| Net Income Per E B T | 1.00 | 1.05 |
BioCryst Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioCryst Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioCryst Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioCryst Pharmaceuticals' important profitability drivers and their relationship over time.
Use BioCryst Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.BioCryst Pharmaceuticals Pair Trading
BioCryst Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioCryst Pharmaceuticals position
In addition to having BioCryst Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Conservative Funds Thematic Idea Now
Conservative Funds
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.